Trial Profile
Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by daclatasvir and asunaprevir combination therapy in genotype 1 HCV-infected hemodialysis patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2018
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- 05 Mar 2018 Status changed from recruiting to completed.
- 11 Aug 2017 New trial record